The board of the United Kingdom’s largest private hospital operator has signaled its support for a Spire Healthcare buyout proposal valued at approximately £1bn. The non-binding offer comes from funds advised by Toscafund Asset Management, a hedge fund managed by the prominent activist investor Martin Hughes.
The announcement sent Spire’s shares soaring by nearly 50% on Thursday, as investors reacted to a bid of 250p per share. This surge follows a period of significant volatility for the company, whose share price had plummeted to a five-year low of 142p in March before the current bidding interest materialized.
Spire Healthcare, which manages a vast network of facilities including St Anthony’s hospital in south London and the Claremont hospital in Sheffield, confirmed that its board would be “minded to recommend unanimously” the cash offer to shareholders, provided a firm proposal is tabled.
The move marks a pivotal moment for the company, which has been under a strategic review since last September. The board has spent months exploring various options to maximize shareholder value, including discussions with several interested parties to determine if a sale of the business was the most viable path forward.
The Return of ‘The Rottweiler’
The bid is driven by Martin Hughes, a veteran of the City of London who founded Toscafund in 2000. Known in financial circles by the nickname “the Rottweiler” for his aggressive and persistent approach to corporate takeovers, Hughes has a track record of identifying undervalued assets and pushing for structural change.
Toscafund is no stranger to high-stakes acquisitions, having successfully taken the telecoms firm TalkTalk private in a £1.1bn deal in 2021. In the case of Spire, Toscafund is already the company’s second-largest shareholder, giving it a strategic vantage point and a vested interest in the operator’s valuation.
However, the path to a completed deal is not without hurdles. Under strict UK takeover rules, Toscafund must announce a firm intention to make an offer by June 11 or be forced to walk away from the transaction entirely.
A History of Failed Bids
This is not the first time Spire has found itself at the center of a billion-pound tug-of-war. The current proposal mirrors a 2021 attempt by Australia’s Ramsay Healthcare, which also offered 250p per share. While the Spire board accepted the Ramsay bid at the time, it was ultimately rejected by the shareholders.
More recently, Spire entered negotiations with private equity firms Bridgepoint and Triton. Those talks collapsed in March after Triton withdrew from the process, leaving the company in a vulnerable position that arguably paved the way for Toscafund’s intervention.
| Bidder | Offer Price | Outcome | Year |
|---|---|---|---|
| Ramsay Healthcare | 250p per share | Rejected by Shareholders | 2021 |
| Triton/Bridgepoint | Undisclosed | Talks Collapsed | 2024 |
| Toscafund | 250p per share | Board Backed (Pending) | 2025 |
Despite these fluctuations, analysts suggest the current bid has a higher probability of success. Miles Dixon, an analyst at Peel Hunt, noted that because the offer is coming from the second-largest shareholder, the deal is more likely to gain the necessary traction with other investors.
The Intersection of Private Care and the NHS
The potential buyout comes at a time of heightened scrutiny regarding the role of private healthcare in the UK. Spire operates 38 private hospitals and over 60 clinics across Scotland, Wales, and England, reporting that it delivered care to 1.36 million patients in 2025.
A critical component of Spire’s business model is its relationship with the National Health Service (NHS). Just under a third of the company’s total revenue is generated from work performed on behalf of the NHS, specifically elective procedures such as hip and knee replacements designed to reduce public waiting lists.
Spire reported on Thursday that more than 85% of NHS commissioning for the new financial year has already been agreed upon, signaling strong growth for the first quarter. This reliance on public funding continues to fuel a broader debate about the “creeping privatisation” of the health service and the risk of creating a two-tiered system of care.
The wider healthcare infrastructure is also seeing a wave of consolidation. Last August, the NHS landlord Assura was acquired by Primary Health Properties in an £1.8bn deal following a competitive battle with the US private equity giant KKR. This trend suggests that institutional investors see significant long-term value in the UK’s healthcare delivery and real estate assets.
Stakeholders and Strategic Outlook
While Toscafund pushes for a buyout, Spire’s largest shareholder, the global healthcare group Mediclinic, holds just under 30% of the company. Mediclinic’s stance will be decisive in whether the 250p offer reaches the finish line.
The Spire board has maintained that it remains “highly confident” in its ability to succeed as a standalone entity. The company highlighted recent progress in diversifying its revenue streams and improving care quality, noting that growth has been particularly strong among “self-pay” patients who fund their own treatment to avoid both NHS queues and insurance hurdles.
Disclaimer: This article is provided for informational purposes only and does not constitute financial, investment, or legal advice.
The market now looks toward the June 11 deadline for a firm offer from Toscafund. Should the bid proceed, it will likely trigger a detailed review of the company’s operational efficiencies and its long-term contractual relationship with the NHS.
We invite readers to share their thoughts on the evolving landscape of UK healthcare in the comments below.
